Literature DB >> 9468717

Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.

R Mackenzie, A Klistorner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9468717      PMCID： PMC2665423     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

1.  Visual field defect associated with vigabatrin: observational cohort study.

Authors:  L V Wilton; M D Stephens; R D Mann
Journal:  BMJ       Date:  1999-10-30

2.  Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.

Authors:  P Hardus; W M Verduin; G Postma; J S Stilma; T T Berendschot; C W van Veelen
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

3.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

4.  Study is needed of visual field defects associated with any long term antiepileptic drug.

Authors:  G P Rao; F A Fat; G Kyle; J P Leach; D W Chadwick; M Batterbury
Journal:  BMJ       Date:  1998-07-18

5.  Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.

Authors:  V Ponjavic; S Andréasson
Journal:  Doc Ophthalmol       Date:  2001-01       Impact factor: 2.379

6.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

7.  Visual field constriction and electrophysiological changes associated with vigabatrin.

Authors:  Dorothea Besch; Anne Kurtenbach; Eckart Apfelstedt-Sylla; Bettina Sadowski; Dieter Dennig; Christiane Asenbauer; Eberhart Zrenner; Ulrich Schiefer
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

8.  Electro-ophthalmological recovery after withdrawal from vigabatrin.

Authors:  Hellen S Graniewski-Wijnands; Kors van der Torren
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

9.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

10.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.